
Hospital Detox Shakeup and NFL Star Sidelined
Coming soon to iPhone. Already have it? “Listen in Starcast” takes you straight there.
On this episode
About this episode
Friday, October 23, 2026 In today's episode, Dr. Alok Patel (@alokpatelmd) & Adam Rose (@adjoro) cover a phase three trial of nicotinamide riboside in early Parkinson disease. Over 52 weeks, the supplement boosted NAD metabolism but showed no clinical benefit, raising questions for NAD boosting strategies. They also walk through a large hospital comparison of phenobarbital and diazepam for alcohol withdrawal, with similar stays and ventilation rates and fewer self directed discharges on phenobarbital, and why diazepam protocols may stay the course pending randomized trials. Plus: they also discuss national measles trends, FDA warning letters to Amazon and Walmart, and more. Coverage…